206 related articles for article (PubMed ID: 33740629)
1. Survival impact on triple-modal strategy comprising hyperthermia, external radiation, and chemotherapy for unresectable locally advanced (UR-LA) pancreatic ductal adenocarcinoma.
Shimomura O; Oda T; Hashimoto S; Doi M; Hiroshima Y; Numajiri H; Takahashi K; Furuya K; Miyazaki Y; Owada Y; Ogawa K; Ohara Y; Hisakura K; Akashi Y; Enomoto T; Sakurai H
Surg Oncol; 2021 Jun; 37():101542. PubMed ID: 33740629
[TBL] [Abstract][Full Text] [Related]
2. Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial).
Shimomura O; Endo M; Makishima H; Yamada T; Hashimoto S; Numajiri H; Miyazaki Y; Doi M; Furuya K; Takahashi K; Moriwaki T; Hasegawa N; Yamamoto Y; Niisato Y; Kobayashi M; Mizumoto M; Nakai K; Saito T; Hoshiai S; Saida T; Mathis BJ; Mori K; Nakajima T; Tsuchiya K; Sakurai H; Oda T
BMC Cancer; 2023 Jul; 23(1):624. PubMed ID: 37403011
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study.
Takano N; Yamada S; Hirakawa A; Yokoyama Y; Kawashima H; Maeda O; Okada T; Ohno E; Yamaguchi J; Ishikawa T; Sonohara F; Suenaga M; Takami H; Hayashi M; Niwa Y; Hirooka Y; Ito Y; Naganawa S; Ando Y; Nagino M; Goto H; Fujii T; Kodera Y
Nagoya J Med Sci; 2019 May; 81(2):233-239. PubMed ID: 31239592
[TBL] [Abstract][Full Text] [Related]
4. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma.
McIntyre CA; Cohen NA; Goldman DA; Gonen M; Sadot E; O'Reilly EM; Varghese AM; Yu KH; Balachandran VP; Soares KC; D'Angelica MI; Drebin JA; Kingham TP; Allen PJ; Wei AC; Jarnagin WR
J Surg Oncol; 2022 Mar; 125(3):425-436. PubMed ID: 34719035
[TBL] [Abstract][Full Text] [Related]
5. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis.
Mataki Y; Kurahara H; Idichi T; Tanoue K; Hozaka Y; Kawasaki Y; Iino S; Maemura K; Shinchi H; Ohtsuka T
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801465
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression.
Kobayashi M; Mizuno S; Murata Y; Kishiwada M; Usui M; Sakurai H; Tabata M; Ii N; Yamakado K; Inoue H; Shiraishi T; Yamada T; Isaji S
Pancreas; 2014 Apr; 43(3):350-60. PubMed ID: 24622063
[TBL] [Abstract][Full Text] [Related]
7. The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer.
Takano N; Yamada S; Sonohara F; Inokawa Y; Takami H; Hayashi M; Koike M; Fujii T; Kodera Y
Surg Today; 2021 Jul; 51(7):1099-1107. PubMed ID: 33483785
[TBL] [Abstract][Full Text] [Related]
8. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
[TBL] [Abstract][Full Text] [Related]
9. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma.
Yanagimoto H; Satoi S; Yamamoto T; Yamaki S; Hirooka S; Kotsuka M; Ryota H; Ishida M; Matsui Y; Sekimoto M
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486418
[TBL] [Abstract][Full Text] [Related]
10. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
Konstantinidis IT; Warshaw AL; Allen JN; Blaszkowsky LS; Castillo CF; Deshpande V; Hong TS; Kwak EL; Lauwers GY; Ryan DP; Wargo JA; Lillemoe KD; Ferrone CR
Ann Surg; 2013 Apr; 257(4):731-6. PubMed ID: 22968073
[TBL] [Abstract][Full Text] [Related]
12. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.
Cecchini M; Miccio JA; Pahade J; Lacy J; Salem RR; Johnson SB; Blakaj A; Stein S; Kortmansky JS; Johung KL
Pancreas; 2020 Aug; 49(7):904-911. PubMed ID: 32658074
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma.
Hayasaki A; Murata Y; Usui M; Hibi T; Ito T; Iizawa Y; Kato H; Tanemura A; Azumi Y; Kuriyama N; Kishiwada M; Mizuno S; Sakurai H; Yoshida T; Isaji S
Pancreas; 2018 Apr; 47(4):390-399. PubMed ID: 29517632
[TBL] [Abstract][Full Text] [Related]
14. Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report.
Okura R; Takano S; Yokota T; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Miyazaki M; Ohtsuka M
Mol Clin Oncol; 2018 Oct; 9(4):389-393. PubMed ID: 30214727
[TBL] [Abstract][Full Text] [Related]
15. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer.
Okano K; Suto H; Oshima M; Ando Y; Nagao M; Kamada H; Kobara H; Masaki T; Okuyama H; Okita Y; Tsuji A; Suzuki Y
Jpn J Clin Oncol; 2018 May; 48(5):434-441. PubMed ID: 29590448
[TBL] [Abstract][Full Text] [Related]
16. Conversion surgery for initially unresectable locally advanced pancreatic ductal adenocarcinoma after chemotherapy followed by carbon-ion radiotherapy: a case report.
Watanabe Y; Tatsuguchi T; Date K; Shinkawa T; Kuga H; Tamiya S; Nishihara K; Nakano T
J Med Case Rep; 2024 Jan; 18(1):13. PubMed ID: 38200536
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
[TBL] [Abstract][Full Text] [Related]
18. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis.
Lindemann J; du Toit L; Kotze U; Bernon M; Krige J; Jonas E
HPB (Oxford); 2021 Feb; 23(2):173-186. PubMed ID: 33268268
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
20. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement.
Jolissaint JS; Reyngold M; Bassmann J; Seier KP; Gönen M; Varghese AM; Yu KH; Park W; O'Reilly EM; Balachandran VP; D'Angelica MI; Drebin JA; Kingham TP; Soares KC; Jarnagin WR; Crane CH; Wei AC
Ann Surg; 2021 Dec; 274(6):894-901. PubMed ID: 34269717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]